Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKI) are strongly recommended for non‐small‐cell lung cancer (NSCLC) patients harbouring active EGFR mutations, while drug resistance makes exploring resistance mechanisms and seeking effective therapeutic strategies urgent endeavours. Here, EGFR is linked to non-small cell lung carcinoma.